

Micro-immunotherapy & Post-COVID Syndrome



This brochure is for doctors and other health professionals only

Fields of application

Micro-immunotherapy formula

Immunoregulatory objectives

For all patients who have undergone SARS-CoV-2 infection (symptomatic or asymptomatic)



Mitochondrial dysfunction, chronic processes and associated disorders (including unexplained physical and/or mental exhaustion – post-viral chronic fatigue syndrome, poor performance)

Formula MIREG

- 1-2 capsules/day until symptoms improve
- Maintenance therapy:
 10 capsules/month for 3-6 months
- ▶ Dampen inflammation and reduce oxidative stress
- Regulate the immune response
- Optimise mitochondrial function and balance the cell energy metabolism

ADDITIONAL TREATMENT OPTIONS FOR POST-COVID SYNDROME (DEPENDING ON EACH INDIVIDUAL CASE, LABORATORY TEST RESULTS AND EXPERIENCE OF THE DOCTOR/THERAPIST)

Fields of application

Micro-immunotherapy formula

Immunoregulatory objectives

For patients with increased inflammatory markers (symptomatic or asymptomatic)



Uncontrolled inflammation, associated disorders (including muscle and joint pain, headache, general malaise, mild fever or dysthermia, thrombosis) and pre-existing conditions associated with chronic inflammation (obesity, diabetes, autoimmune diseases and others)

Formula ARTH

- Acute conditions: 3-4 capsules/day until symptoms improve
- Maintenance therapy:
 1 capsule/day for 3-6 months

Reduce inflammation and relieve pain

- Limit tissue damage and loss of function
- Avoid transition to chronicity

Formula INFLAM

- Acute conditions: 3-4 capsules/day until symptoms improve
- Maintenance therapy:
 1 capsule/day for 3-6 months

- Reduce inflammation and relieve pain
- ▶ Promote anti-inflammatory signalling pathways
- ▶ Limit harmful metabolic effects of chronic processes

For patients with psychological disorders



Acute or chronic stress (psychological and/or emotional), anxiety, shock, adrenal fatigue, daily overexertion, burnout, exhaustion, immunodeficiency

Formula MISEN

• 1-2 capsules/day for 3-6 months

- ► Regulate the neuro-endocrine-immune axis
- ▶ Prevent immunodeficiency and strengthen immune defence
- Promote cell regulation and rejuvenation by maintaining telomerase activity



Depressive mood, mild depression, inflammation-induced fatigue syndrome with depressive component, burnout

Formula DEP

• 1-2 capsules/day for 3-6 months

- ▶ Balance the activity of the stress axis
- ▶ Dampen inflammation and recover the TH1-TH2-TH3 balance
- Promote neuroregeneration and neuroplasticity

	Fields of application	Micro-immunotherapy formula	Immunoregulatory objectives
		For patients with mental disorders	
	Memory disorders, lack of concentration	Formula MEM-SENIOR • 1 capsule/day for 6 months or longer	 Dampen inflammation and reduce oxidative stress Promote neuroprotection and neuroregeneration Improve memory performance
	Tendency towards dementia	Formula MdA • 1 capsule/day for 6 months or longer	 Dampen inflammation, reduce oxidative stress and limit neurodegeneration Promote neuroprotection and neuroregeneration Modulate the β-amyloid metabolism Improve memory performance and mental well-being
For patients with immune disorders and/or microbial burden (symptomatic or asymptomatic), depending on serology results and lymphocyte typing			
17	Immunodeficiency / immune exhaustion or non-adaptation of the immune system with lymphopenia / hyporeactivity and associated disorders (including opportunistic infections, flu-like symptoms, weakness, sore throat)	Formula EID or EID-N 1-2 capsules/day for 3-6 months	 Strengthen post-infection immunity on the cellular and humoral level Promote host defence and immune regulation
<u> </u>	Non-adaptation of the immune system with lymphocytosis / hyperreactivity or tendency towards autoimmunity and associated disorders (including uncontrolled inflammation, fever episodes, muscle pain, unspecified neurological symptoms, insomnia, sweating)	Formula EAI • 1 capsule/day for 1-2 months	 Control excessive immune response, limit autoreactive phenomena mediated primarily by B and T cells, and prevent their persistence Promote immune tolerance
***	Coinfection or viral reactivation and associated disorders (including post-viral chronic fatigue syndrome, wandering joint and muscle pain, swollen cervical lymph nodes)	Formula EBV / CMV / ZONA / HERP (EBV, CMV, VZV and HSV infection with lymphopenia/hyporeactivity) • 1-2 capsules/day for 3-6 months Formula XFS (EBV and CMV infection with hyperreactivity) • 1 capsule/day for 1-2 months	 Contain viral proliferation and infection of further cells Support the antiviral immune response Control persistent infections and associated diseases

DIAGNOSIS OF POST-COVID SYNDROME

For patients with mild, moderate or severe post-COVID syndrome

Full blood count, erythrocyte sedimentation rate (ESR); blood chemistry testing (including transaminases, cystatin C, creatinine, glomerular filtration rate - GFR); glucose, cholesterol, triglycerides; SARS-CoV-2 serology; serum electrophoresis or immunoelectrophoresis; ultrasensitive C-reactive protein; D dimer and other coagulation factors; vitamin D status; iron status; thyroid (TSH, fT3, fT4) and thyroid antibody levels, micronutrient status

For patients undergoing stress

Cortisol and DHEA in the daily profile; sex hormones; catecholamines; aldosterone; serotonin

In case of suspicion of immune disorders and microbial burden

Lymphocyte typing, serology for Epstein Barr virus (EBV), cytomegalovirus (CMV), varicella zoster virus (VZV), herpes simplex virus 1 and 2 (HSV) or human herpesvirus 6 (HHV6)

Other diagnostic options in case of suspicion of uncontrolled inflammation and other immune disorders

Serum protein profile, T helper cell status, inflammation profile (depending on each individual case)



Please note:



The statements made in this brochure are based on the current state of knowledge regarding post-COVID syndrome and on the knowledge and experience of doctors/therapists of micro-immunotherapy associations. They have been validated by Dr Petra Blum. This brochure is only intended to make readers aware of potential immune disorders following SARS-CoV-2 infection and to provide an indicative guide for the treatment with micro-immunotherapy.

Please do not make any diagnosis or initiate any treatment plan solely on the basis of this brochure. Each individual case must be analysed, and a treatment plan drawn up based on the clinical history of each patient, laboratory tests (including lymphocyte typing and serologies) and personal practical experience.

Micro-immunotherapy associations assume no liability for any diagnoses you may make or treatment plans you may initiate.

Contact us / visit our website:

micro-immunotherapy@micro-immunotherapy.com www.micro-immunotherapy.com

